What question did this study set out to answer?

This research aims to investigate the defective protein trafficking of the N470D HERG mutant in Long QT Syndrome and evaluate pharmacological interventions.

October 1, 1999Journal of Biological ChemistryOpen Access

Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome

View Full Paper

Ask AI

Bookmark

This research aims to investigate the defective protein trafficking of the N470D HERG mutant in Long QT Syndrome and evaluate pharmacological interventions.
Evaluated protein trafficking of N470D HERG mutant in HEK293 cells at temperatures 27 degrees C and 37 degrees C.
Tested the effects of antiarrhythmic drugs, including E-4031, astemizole, and cisapride, on HERG channel function.
Assessed drug concentration effects and the mechanism of action on protein trafficking post-translationally.
At 37 degrees C, the N470D mutant showed defective trafficking; improved trafficking and function were observed at 27 degrees C.
E-4031 significantly corrected the trafficking defect in a concentration-dependent manner, resulting in restored HERG current.
Similar trafficking restoration was noted with astemizole, cisapride, and glycerol, indicating potential pharmacological treatment options.

Structured PICO

Population

HEK293 cells expressing the N470D LQT2 mutant protein

Intervention

E-4031 (up to 5 microM), astemizole, cisapride, high concentrations of glycerol, or incubation at 27 degrees C

Comparator

Incubation at 37 degrees C without pharmacological intervention

Outcome

Correction of defective protein trafficking to the plasma membrane and restoration of HERG currentsurrogate

Pharmacological strategies using specific HERG blockers can correct protein misfolding and defective trafficking of some HERG LQT mutations in vitro.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Does not support clinical use of HERG blockers for LQT2 trafficking defects; leaves open further preclinical validation of pharmacological rescue.

Cite This Study

Zhou et al. (1999) studied this question.

synapsesocial.com/papers/6a0f9dcad03631df9ce9ccde https://doi.org/10.1074/jbc.274.44.31123

View Full Paper

Ask AI

Bookmark

Implication

Does not support clinical use of HERG blockers for LQT2 trafficking defects; leaves open further preclinical validation of pharmacological rescue.

Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider